Quince Therapeutics (QNCX) Shares Outstanding (2018 - 2026)
Quince Therapeutics (QNCX) posted quarterly Shares Outstanding (Entity) of $456013.0 for Q1 2026, up 106.86% year-over-year from $220446.0 in Q1 2025, and up 63.66% quarter-over-quarter from $278626.0 in Q4 2025.
Quince Therapeutics (QNCX) Shares Outstanding (2018 - 2026) Analysis & Trends
Quince Therapeutics' Shares Outstanding (Entity) history runs 9 years deep, the most recent figure standing at $456013.0 for Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 106.86% year-over-year to $456013.0; the TTM figure through Mar 2026 stood at $456013.0 (up 106.86% YoY), while the FY2025 annual figure was $278626.0, up 26.64% from the prior year.
- Shares Outstanding (Entity) for Q1 2026 stood at $456013.0, up from $278626.0 in the prior quarter.
- The five-year high for Shares Outstanding (Entity) was $456013.0 in Q1 2026, with the low at $150748.0 in Q1 2022.
- The 5-year median for Shares Outstanding (Entity) is $216076.0 (2024), against an average of $224477.5.
- The sharpest annual moves came in 2023 and 2026: Shares Outstanding (Entity) gained 0.59% in 2023, then jumped 106.86% in 2026.
- Quince Therapeutics' Shares Outstanding (Entity) stood at $180682.0 in 2022, then grew by 18.92% to $214866.0 in 2023, then advanced by 2.39% to $220008.0 in 2024, then grew by 26.64% to $278626.0 in 2025, then jumped by 63.66% to $456013.0 in 2026.
- Business Quant data shows QNCX's Shares Outstanding (Entity) at $456013.0 in Q1 2026, $278626.0 in Q4 2025, and $272475.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | Quince Therapeutics | 203.43 Mn | 203.43 Mn | - | 6.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 456,013.00 |
| Dec 31, 2025 | 250,484.00 |
| Sep 30, 2025 | 269,757.00 |
| Jun 30, 2025 | 233,431.00 |
| Mar 31, 2025 | 219,706.00 |
| Dec 31, 2024 | 216,311.00 |
| Sep 30, 2024 | 215,821.00 |
| Jun 30, 2024 | 215,482.00 |
| Mar 31, 2024 | 215,051.00 |
| Dec 31, 2023 | 186,186.00 |
| Sep 30, 2023 | 180,365.00 |
| Jun 30, 2023 | 179,588.00 |
| Mar 31, 2023 | 179,276.00 |
| Dec 31, 2022 | 167,483.00 |
| Sep 30, 2022 | 178,064.00 |
| Jun 30, 2022 | 162,335.00 |
| Mar 31, 2022 | 150,672.00 |
| Dec 31, 2021 | 148,593.00 |
| Sep 30, 2021 | 148,837.00 |
| Jun 30, 2021 | 147,937.00 |